A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Blood

• Publication date

  2005-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1182/BLOOD-2005-03-1153PMID 16014562
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutagenesisによる血小板糖蛋白（GP）Ibα von Willebrand Factor（VWF）結合における制御機構の解析

  2007cited by this paper
• An Experimental Model to Study the in Vivo Survival of von Willebrand Factor

  2004cited by this paper
• Crystal Structure of the Wild-type von Willebrand Factor A1-Glycoprotein Ibα Complex Reveals Conformation Differences with a Complex Bearing von Willebrand Disease Mutations*

  2004cited by this paper
• Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw–Schulman syndrome)

  2004cited by this paper
• Mapping the Collagen-binding Site in the von Willebrand Factor-A3 Domain*

  2003cited by this paper
• Von Willebrand factor, platelets and endothelial cell interactions

  2003cited by this paper
• Von Willebrand factor

  2003cited by this paper
• Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.

  2003cited by this paper
• Identification of the regulatory elements of the human von Willebrand factor for binding to platelet GPIb. Importance of structural integrity of the regions flanked by the CYS1272-CYS1458 disulfide bond

  2003cited by this paper
• von Willebrand Factor

  2002cited by this paper
• Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers.

  2002cited by this paper
• Thrombotic microangiopathies.

  2002cited by this paper
• von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

  2002cited by this paper
• Identification of the Regulatory Elements of the Human von Willebrand Factor for Binding to Platelet GPIb

  2002cited by this paper
• ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.

  2002cited by this paper
• Structures of Glycoprotein Ibα and Its Complex with von Willebrand Factor A1 Domain

  2002cited by this paper
• Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.

  2001cited by this paper
• Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

  2001cited by this paper
• Partial amino acid sequence of purified von Willebrand factor-cleaving protease.

  2001cited by this paper
• How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

  2000cited by this paper
• Platelet thrombus formation on collagen at high shear rates is mediated by von Willebrand factor-glycoprotein Ib interaction and inhibited by von Willebrand factor-glycoprotein IIb/IIIa interaction.

  2000cited by this paper
• Biochemistry and genetics of von Willebrand factor.

  1998cited by this paper
• Functional studies on platelet adhesion with recombinant von Willebrand factor type 2B mutants R543Q and R543W under conditions of flow.

  1997cited by this paper
• Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies

  1997cited by this paper
• Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.

  1996cited by this paper
• A3 Domain Is Essential for Interaction of von Willebrand Factor with Collagen Type III

  1996cited by this paper
• Structure and Function of von Willebrand Factor

  1992cited by this paper
• Efficient plasma membrane expression of a functional platelet glycoprotein Ib-IX complex requires the presence of its three subunits.

  1992cited by this paper
• Thrombotic microangiopathies.

  1991cited by this paper
• Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets.

  1991cited by this paper
• Identification of a site in the alpha chain of platelet glycoprotein Ib that participates in von Willebrand factor binding.

  1990cited by this paper
• Ristocetin-dependent reconstitution of binding of von Willebrand factor to purified human platelet membrane glycoprotein Ib-IX complex.

  1988cited by this paper
• Assembly of a functional immunoglobulin Fv fragment in Escherichia coli.

  1988cited by this paper
• von Willebrand factor and von Willebrand disease.

  1987cited by this paper
• Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.

  1986cited by this paper
• Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain.

  1983cited by this paper
• Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.

  1980cited by this paper
• Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein.

  1977cited by this paper

• Molecular Basis of Thrombotic Microangiopathy.

  2025cites this paper
• Elevated levels of (active) von Willebrand Factor during anticoagulation are associated with early recurrence of venous thromboembolism.

  2025cites this paper
• Quantitative Systems Pharmacology Modeling of Platelet Responses to Recombinant ADAMTS13 in Patients With Congenital Thrombotic Thrombocytopenic Purpura

  2025cites this paper
• O-glycan determinants regulate VWF trafficking to Weibel-Palade bodies

  2024cites this paper
• Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs

  2024cites this paper
• Interpreting high levels of unfolded Von Willebrand Factor in patients with the antiphospholipid syndrome

  2024cites this paper
• Conformation-specific RNA aptamers for phenotypic distinction between normal von Willebrand factor and type 2B von Willebrand disease

  2024cites this paper
• Von Willebrand factor: how unique structural adaptations support and coordinate its complex function.

  2024cites this paper
• Implications of von Willebrand Factor in Inflammatory Bowel Diseases: Beyond Bleeding and Thrombosis.

  2024cites this paper
• Conformational activation and inhibition of von Willebrand factor by targeting its autoinhibitory module.

  2024cites this paper
• The role of platelets and von Willebrand factor in the procoagulant phenotype of inflammatory bowel disease.

  2023cites this paper
• Nanobodies as Diagnostic and Therapeutic Tools for Cardiovascular Diseases (CVDs)

  2023cites this paper
• Physical Characteristics of von Willebrand Factor Binding with Platelet Glycoprotein Ibɑ Mutants at Residue 233 Causing Various Biological Functions

  2022cites this paper
• The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse

  2022cites this paper
• Insights in the Prothrombotic Changes After Implantation of a Left Ventricular Assist Device in Patients With End-Stage Heart Failure: A Longitudinal Observational Study

  2022cites this paper
• A nanobody against the von Willebrand factor A3-domain detects ADAMTS13-induced proteolysis in congenital & acquired VWD.

  2022cites this paper
• A Novel Nanobody-Horseradish Peroxidase Fusion Based-Competitive ELISA to Rapidly Detect Avian Corona-Virus-Infectious Bronchitis Virus Antibody in Chicken Serum

  2022cites this paper
• Functional changes in hemostasis during asexual and sexual parasitemia in a controlled human malaria infection

  2022cites this paper
• Osteoprotegerin modulates platelet adhesion to von Willebrand factor during release from endothelial cells

  2021cites this paper
• Prothrombotic state associated with preeclampsia

  2021cites this paper
• Diverse activities of von Willebrand factor in traumatic brain injury and associated coagulopathy

  2020cites this paper
• Increased von Willebrand Factor Processing in COPD, Re fl ecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk

  2020cites this paper
• Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk

  2020cites this paper
• Conformation-Dependent Blockage of Activated VWF Improved Outcomes of Traumatic Brain Injury in Mice.

  2020cites this paper
• Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications

  2020cites this paper
• The Therapeutic Potential of Nanobodies

  2019cites this paper
• Ulinastatin attenuates vascular endothelial cell damage in pregnant women with severe pre-eclampsia.

  2019cites this paper
• Analytical characterization and reference interval of an enzyme-linked immunosorbent assay for active von Willebrand factor

  2019cites this paper
• Haemostasis and Parasitic Helminths

  2019cites this paper
• A single‐domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor

  2019cites this paper
• Haemostatic changes in urogenital schistosomiasis haematobium: a case-control study in Gabonese schoolchildren.

  2019cites this paper
• Von Willebrand Factor Adhesive Activity and ADAMTS13 Protease Activity in HIV-1-Infected Men

  2019cites this paper
• 5 Von Willebrand Factor-Mediated Thrombotic Microangiopathies

  2018cites this paper
• Von Willebrand factor contribution to pathophysiology outside of von Willebrand disease

  2018cites this paper
• Effects of Repeated Bouts of Exercise on the Hemostatic System

  2018cites this paper
• Inflammation, von Willebrand factor, and ADAMTS13.

  2018cites this paper
• A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor

  2017cites this paper
• von Willebrand factor and inflammation

  2017cites this paper
• Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso‐occlusive crisis and steady state

  2017cites this paper
• Type 2B von Willebrand disease with or without large multimers: A distinction of the two sides of the disorder is long overdue

  2017cites this paper
• Platelets in infectious diseases: the silent force

  2017cites this paper
• Effects of Yunnan Baiyao on blood coagulation parameters in beagles measured using kaolin activated thromboelastography and more traditional methods

  2017cites this paper
• Therapeutic targets in sickle cell disease

  2017cites this paper
• Platelet dysfunction contributes to bleeding complications in patients with probable leptospirosis

  2017cites this paper
• The and the tails of malaria and VWF

  2016cites this paper
• A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis

  2016cites this paper
• Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality

  2016cites this paper
• The contribution of von Willebrand factor–GPIbα interactions to persistent aggregate formation in apheresis platelet concentrates

  2016cites this paper
• Endothelial activation, haemostasis and thrombosis biomarkers in Ugandan children with severe malaria participating in a clinical trial

  2016cites this paper
• The heads and the tails of malaria and VWF.

  2016cites this paper
• Diagnostics différentiels du PTT à l’admission : étiologies et impact sur l'évolution des patients. Expérience du Centre de Référence Français des Microangiopathies Thrombotiques

  2016influential citation
• Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination

  2015cites this paper
• Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease.

  2015cites this paper
• Higher and lower active circulating VWF levels: different facets of von Willebrand disease

  2015cites this paper
• von Willebrand activation factor as a marker of mortality, cardiovascular events, and bleeding complications in patients treated with oral anticoagulants.

  2015cites this paper
• Platelet‐dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH

  2015cites this paper
• Interaction of von Willebrand factor with platelets and the vessel wall

  2015cites this paper
• Co-expression of Factor VIII with anti-FVIII Camelid antibody ligands: Effect on expression levels of bio-therapeutic FVIII

  2015cites this paper
• Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: A multicenter and multiethnic study

  2015cites this paper
• History of Thrombotic Thrombocytopenic Purpura and the von Willebrand Factor–Cleaving Protease, ADAMTS13

  2015cites this paper
• Engineered Antibody Domains as Candidate Therapeutics

  2014cites this paper
• von Willebrand Disease: Biological Diagnosis

  2014cites this paper
• Platelet degranulation and glycoprotein IIbIIIa opening are not related to bleeding phenotype in severe haemophilia A patients

  2014cites this paper
• Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice.

  2014cites this paper
• Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome.

  2014cites this paper
• Factor VIII concentrate infusion in patients with haemophilia results in decreased von Willebrand factor and ADAMTS‐13 activity

  2014cites this paper
• Nanobodies as novel agents for disease diagnosis and therapy

  2013cites this paper
• Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia.

  2013cites this paper
• 2B or not 2B: when VWF is not a good platelet friend.

  2013cites this paper
• The type 2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress

  2013cites this paper
• Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation.

  2013cites this paper
• Chapter 20 – Platelet Thrombus Formation in Flowing Blood

  2013cites this paper
• Perils, Problems, and Progress in Laboratory Diagnosis of von Willebrand Disease

  2013cites this paper
• Platelet function in bleeding disorders

  2013cites this paper
• adhesion and aggregation dependent platelet - 2-Glycoprotein I inhibits von Willebrand factor β

  2013cites this paper
• The Interaction between Factor H and Von Willebrand Factor

  2013cites this paper
• Novel therapy based on camelid nanobodies.

  2013cites this paper
• Folding and aggregation of a multi-domain engineered immunotoxin

  2013cites this paper
• Platelet interaction with von Willebrand factor is enhanced by shear-induced clustering of glycoprotein Ibα

  2013cites this paper
• Von Willebrand factor and thrombosis: risk factor, actor and pharmacological target.

  2013cites this paper
• Assembling the machinery of coagulation.

  2013cites this paper
• Unwinding the von Willebrand factor strings puzzle.

  2013cites this paper
• Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia

  2013cites this paper
• THROMBOSIS AND HEMOSTASIS No increase in bleeding identi fi ed in type 1 VWD subjects with D 1472 H sequence variation

  2013cites this paper
• Proteolytic Processing of Von Willebrand Factor by Adamts13 and Leukocyte Proteases

  2013cites this paper
• No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.

  2013cites this paper
• A nanobody-based method for tracking factor XII activation in plasma

  2013cites this paper
• Comment on Casari et al , page 2893 2 B or not 2 B : when VWF is not a good platelet friend

  2013cites this paper
• Advances in Management of Crohn’s Disease

  2012cites this paper
• Severe Dengue Is Associated with Consumption of von Willebrand Factor and Its Cleaving Enzyme ADAMTS-13

  2012cites this paper
• von Willebrand factor: at the crossroads of bleeding and thrombosis

  2012influential citation
• A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13.

  2012cites this paper
• Inflammatory bowel diseases: emerging therapies and promising molecular targets.

  2012cites this paper
• Indications for a protective function of beta2‐glycoprotein I in thrombotic thrombocytopenic purpura

  2012cites this paper
• Variable fragments of heavy chain antibodies (VHHs): a new magic bullet molecule of medicine?

  2012cites this paper
• Investigations into the regulation of the hemostatic response

  2012cites this paper
• Von Willebrand Factor-Mediated Thrombotic Microangiopathies

  2012cites this paper
• Surface Analysis of Adsorbed Proteins: A Multi-Technique Approach to Characterize Surface Structure

  2012cites this paper
• The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.

  2011cites this paper
• SELECTION OF EPITOPE DIRECTED RECOMBINANT ANTIBODIES TO INHIBIT MUTATED NUCLEOPHOSMIN ACTIVITIES

  2011cites this paper